
%0 Journal Article
%A Tietze, Lutz F. 
%A Feuerstein, Tim 
%T <emph type="2">Review:</emph> Highly Selective Compounds for the Antibody-Directed Enzyme Prodrug Therapy of Cancer
%J Australian Journal of Chemistry
%D 2003/08/08
%V 56
%N 9
%P 841-854
%K 
%R https://doi.org/10.1071/CH03036
%U https://www.publish.csiro.au/paper/CH03036 
%X Antibody-directed enzyme prodrug therapy (ADEPT) is a recent development for a selective treatment of cancer, based on site-directed formation at the surface of malignant cells of cytotoxic compounds from non-toxic prodrugs with a conjugate of an appropriate enzyme and a monoclonal antibody which binds to tumour-associated antigens. New potent prodrugs of analogues of the antibiotic CC-1065 have been developed. These show a remarkable selectivity with a Q(IC50) value of up to more than 3000. Moreover, the formed drug has a high potency with an IC50 of 30 pM. 
